Skip to content
type1.science
Phase 2RecruitingNCT06111586

FABULINUS: Frexalimab CD40L blockade in recent-onset T1D

Sanofi phase-2b trial of frexalimab, a CD40L antagonist, to preserve endogenous insulin secretion in adolescents and adults with newly diagnosed T1D.

Primary endpoints

  • C-peptide preservation over 52 weeks

Results so far

No T1D efficacy results published yet.

The full picture

FABULINUS is one of the most important active immunotherapy trials to track because it tests CD40L costimulation rather than another anti-CD3, JAK or antigen-specific approach.